Search the Newsreel

Johnson & Johnson Announces Collaboration with Sail Biomedicines to Advance in vivo CAR-T Programs and Transform Autoimmune Disease Through Immune Reset

Advances differentiated immunology program with the potential to address significant unmet need in immune-mediated disease Novel in vivo CAR-T platform is designed to generate CAR-T therapies directly within the body, enabling scalable treatments with durable, disease-modifying, and curative potential Strengthens Johnson & Johnson's leadership …

Explainer-Can J&J finally put the talc litigation behind it?

By Dietrich Knauth NEW YORK, July 29 (Reuters) - After years of failed attempts to resolve thousands of lawsuits alleging that its talc products caused cancer, Johnson & Johnson says it has reached a settlement, worth at least $5.5 billion, that could finally help …

Johnson & Johnson vs. Eli Lilly: Reliable Stability vs. Rapid Revenue Growth

Key Points Eli Lilly currently displays stronger upward momentum in top-line growth, whereas Johnson & Johnson maintains a higher but flatter overall baseline. Over roughly the last eight quarters, the two companies experienced diverging patterns, with Johnson & Johnson staying mostly stable quarter over …

Johnson & Johnson proposes $5.5B settlement to resolve remaining talc litigation

Johnson & Johnson proposes $5.5B settlement to resolve remaining talc litigation Proactive uses images sourced from Shutterstock Johnson & Johnson (NYSE:JNJ) has reached an agreement to resolve tens of thousands of lawsuits in the US alleging that its talc-based products, including its baby powder, …

What Johnson & Johnson Stock Told You Before It Surged

Photo by kravaivan11 on Pixabay Johnson & Johnson stock's oncology engine and its steady guidance raises were on the record quarters before the price moved. A Run That Matched Merck And More Than Tripled The S&P Over the year from late July 2025, Johnson …

Johnson & Johnson (JNJ) Stock May Be 31% Undervalued As Myeloma Trial Results Impress

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Johnson & Johnson stock has delivered a 77.7% total return over the past five …

Johnson & Johnson settling talc baby powder lawsuits for $5.5 billion

Johnson & Johnson announced an agreement Monday to pay $5.5 billion to resolve tens of thousands of lawsuits claiming its talc-based baby powder and other talc products caused ovarian cancer, a settlement the company said would bring finality to 15 years of litigation. The …

Johnson & Johnson proposes $5.5 billion talc settlement to end marathon legal fight

Johnson & Johnson has agreed to pay $5.5 billion to tie up remaining lawsuits that claim its talc products caused ovarian cancer. The drugmaker, which has been fighting talc-related lawsuits for more than a decade, said that the settlement is conditioned on at least …

Johnson & Johnson offers £4.1bn to settle talcum powder cancer claims

The settlement covers around 76,000 claims that J&J's baby powder caused cancer - Firdous Nazir/NurPhoto Johnson & Johnson (J&J) has agreed to pay an estimated $5.5bn (£4.1bn) to resolve tens of thousands of claims that its baby powder caused ovarian cancer. The pharmaceutical giant's …

Johnson & Johnson Proposes to Pay Up to $5.5 Billion to Resolve Remaining Ovarian Cancer Claims

Johnson & Johnson (JNJ) has agreed to commit up to $5.5 billion to settle about 76,000 lawsuits that PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. …

Johnson & Johnson Strikes $5.5 Bln Talc Settlement Deal, Subject To 95% Claimant Approval

(RTTNews) - Johnson & Johnson (JNJ) on Monday announced that it has reached an agreement to resolve the remaining talc litigation with the plaintiff firms leading the federal Multi-District Litigation (MDL) and related state court proceedings. The resolution includes a $5.5 billion commitment to …

J&J offers $5.5bn to settle baby powder lawsuits

Johnson & Johnson (J&J) has offered to pay $5.5bn (£4.13bn) to resolve tens of thousands of lawsuits in the US alleging its talcum powder caused ovarian cancer. The company said the settlement covers around 76,000 claims, having already settled most cases alleging its talc …

Johnson & Johnson to pay up to $5.5B to settle talc lawsuits

Wachiwit/iStock Editorial via Getty Images Johnson & Johnson (JNJ [https://seekingalpha.com/symbol/JNJ]) up 1.4% post-market Monday after saying it agreed to pay up to $5.5B to settle remaining lawsuits [https://seekingalpha.com/pr/20596634-johnson-and-johnson-announces-a-proposed-resolution-of-ovarian-talc-litigation] that alleged its talc products caused ovarian cancer. The company said it reached an agreement for …

Johnson & Johnson Announces a Proposed Resolution of Ovarian Talc Litigation

Follows Favorable Multi-District Litigation Court Causation Ruling and the Company's Successful Strategy to Defend Each Case Efficient Conclusion to the Talc Litigation that Eliminates Expense Associated with Litigating Remaining Roughly 76,000 Ovarian Talc Claims NEW BRUNSWICK, N.J., July 27, 2026--(BUSINESS WIRE)--Johnson & Johnson (NYSE: …

Johnson & Johnson (JNJ) Raised Its Outlook. Is It the Better Healthcare Stock to Own After Earnings?

Johnson & Johnson (NYSE:JNJ) delivered strong fiscal Q2 2026 results, with sales for the quarter growing nearly 7% to $25.31 ⁠billion, above analysts' average estimate of about $25.05 billion. Adjusted earnings per share reached $2.90, surpassing the expectation of $2.85. The company also raised …

Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer

Kymera Therapeutics, Inc. Dr. Rooney, former immunology leader at Johnson & Johnson, will lead clinical development strategy across Kymera's industry-leading oral immunology portfolio Jared Gollob, MD, will retire from his role after eight years of leadership at the Company WATERTOWN, Mass., July 27, 2026 …

J&J's MedTech Performance Slows in Q2: Will Sales Improve in H2?

Johnson & Johnson's JNJ medical devices segment, known as MedTech, offers products in the orthopedics, surgery, cardiovascular and vision markets. The MedTech segment accounts for around 36% of J&J's total revenues. In MedTech, J&J is a global leader in electrophysiology, circulatory restoration and heart …

Forget Social Security: 5 Sleep-at-Night Dividend Stocks Retirees Are Using to Replace a Paycheck

Quick Read Realty Income (O) yields 5.11% with 670 consecutive monthly dividends, while Verizon (VZ) anchors the group at a 6.46% yield. All five stocks raised dividends through two recessions with cash flow covering each payout, making them viable alternatives to Social Security's 2.8% …

President Trump Loves Johnson & Johnson (JNJ), But Insiders Are Selling

Johnson & Johnson (NYSE:JNJ) is one of the health care names that showed up in President Donald Trump's financial disclosures released earlier this year. Now a top J&J executive is heading the other direction. The Insider Sale EVP of Global Corporate Affairs Vanessa Broadhurst …

Zacks Investment Ideas feature highlights: General Motors, Abbott Laboratories and Johnson & Johnson

For Immediate Release Chicago, IL – July 27, 2026 – Today, Zacks Investment Ideas feature highlights General Motors GM, Abbott Laboratories ABT and Johnson & Johnson JNJ. Q2 Earnings: Guidance Upgrades Push These 3 Stocks Higher The 2026 Q2 earnings season will continue at …

Better Dividend King to Buy Right Now: AbbVie or Johnson & Johnson?

Key Points These two companies are pharmaceutical giants. Both seem somewhat overvalued at recent levels. Still, they're likely to do well over the long term.10 stocks we like better than AbbVie › Dividend Kings are companies that have increased their dividends for 50 or …

Jim Cramer Said To Buy Johnson & Johnson (NYSE:JNJ)’s Shares – Here’s What Happened Next

Healthcare giant Johnson & Johnson (NYSE:JNJ) is one of Jim Cramer's top healthcare stocks even though the shares have been lackluster. They are up by a modest 27% year-to-date, with most of the gains having come since mid-June. Since June 18th, Johnson & Johnson …

Johnson & Johnson (JNJ) Reports Early Phase 3 Win In Multiple Myeloma

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Johnson & Johnson reported highly positive interim Phase 3 results for the TECVAYLI + …

Q2 Earnings: Guidance Upgrades Push These 3 Stocks Higher

The 2026 Q2 earnings season will continue at a rapid pace in the coming weeks, with many notable companies on the reporting docket. The big banks helped kick the period off positively, though post-earnings reactions haven't been great for all that have reported. But …

FDA Approves Johnson & Johnson Table-Integrated OTTAVA Robotic Surgery System

Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. The U.S. Food and Drug Administration on Wednesday granted De Novo authorization for Johnson & Johnson's OTTAVA Robotic Surgical System, marking the regulatory clearance of the world's …

ETFs to Buy Post JNJ's Q2 Earnings Beat & Bullish 2026 Outlook

Medtech giant Johnson & Johnson JNJ reported better-than-expected second-quarter 2026 results, surpassing Wall Street estimates on both the top and bottom lines. The quarterly performance was primarily driven by strong growth in the immunology drug Tremfya and cancer blockbuster Darzalex. Despite reporting such an …

TECVAYLI® + TALVEY® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma

Investigational MonumenTAL-6 trial is the first and only Phase 3 study of a dual antigen, BCMA and GPRC5D targeting regimen in relapsed/refractory multiple myeloma Fifth positive Phase 3 study evaluating Johnson & Johnson's multiple myeloma T-cell therapy portfolio in second line, further strengthening the …

Should FDA’s De Novo Nod for OTTAVA Robotic System Require Action From Johnson & Johnson (JNJ) Investors?

Earlier this week, Johnson & Johnson announced that the FDA had granted De Novo authorization for its OTTAVA Robotic Surgical System, a table‑integrated soft tissue platform cleared for a range of general surgery procedures including Roux-en-Y gastric bypass, gastrectomy, cholecystectomy and appendectomy. This authorization …

Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know

Johnson & Johnson (JNJ) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future. Over the past month, shares of this world's …

J&J enters US robotic surgery market after device gets marketing authorization

By Puyaan Singh July 22 (Reuters) - Johnson & Johnson said on Wednesday the U.S. Food and Drug Administration had granted marketing authorization for its robotic surgery ‌device, as the healthcare conglomerate enters the soft-tissue robotic surgery market. The decision ‌marks a key step …

Johnson & Johnson Receives FDA Market Authorization in the U.S. for its OTTAVA™ Robotic Surgical System

Built to open new possibilities in surgery, OTTAVA™ creates a new category in soft tissue robotics System authorized for use in multiple procedures in general surgery within the upper abdomen System features are designed to enable surgical teams and hospitals to expand OR capacity, …

Johnson & Johnson (JNJ) Raised Its Dividend, Where Does Fair Value Sit?

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Johnson & Johnson (JNJ) has declared a third quarter 2026 cash dividend of $1.34 per share, providing income focused investors with fresh information on the …

Correction: Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight

DelveInsight Business Research LLP The head and neck squamous cell carcinoma market is experiencing significant growth, driven by the rising incidence of head and neck cancers worldwide, increasing adoption of immunotherapies, targeted therapies, and combination treatment approaches. Additionally, the expected launch of emerging therapies …

MedTech Pioneer Max Reinhardt Joins eXeX to Drive Canopus Platform Growth

The Johnson & Johnson, Pacira BioSciences and Orthofix executive takes charge of commercial execution as adoption of Canopus by eXeX accelerates across hospital systems in the United States and United Kingdom, and as eXeX launches Canopus Command, the first portal to give hospital leadership …

Johnson & Johnson (JNJ) Buys Spine Tech And Wins FDA Nod For Heart Device

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. DePuy Synthes, part of Johnson & Johnson MedTech, has acquired spine surgery company Expanding Innovations, adding new expandable interbody technologies to its portfolio. Johnson & Johnson has …

What's behind Johnson & Johnson's latest stock surge?